' 
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
6.9
USERS' SCORE
Very Good
Based on 2 Reviews
7.9
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%
Saturated Fat
0 g
0%
Trans Fat
0 g
**
Polyunsaturated Fat
0.5 g
**
Monounsaturated Fat
0 g
**
Cholesterol
10 mg
3%
Omega-3 Fish Oil
1000 mg
**
EPA (Eicosapentaenoic Acid)
180 mg
**
DHA (Docosahexaenoic Acid)
120 mg
**
Top Medical Research Studies
8
Eicosapentaenoic acid benefits atherosclerosis
The effect of omega-3 polyunsaturated fatty acid intake on blood levels of omega-3s in people with chronic atherosclerotic disease: a systematic review.
Highly relevant omega-3 supplementation study
We set out to understand how eicosapentaenoic acid (a type of omega-3 fatty acid) influences blood levels in individuals suffering from chronic atherosclerotic disease. This study synthesized findings from 25 articles, focusing on randomized controlled trials that investigated omega-3 supplementation specifically for this patient group.
Our exploration revealed that dosages between 1.8 grams and 3.4 grams per day, over a span of three to six months, were effective in elevating omega-3 levels to therapeutic targets. Higher doses, at 4.4 grams or more, showed similar benefits even with a shorter supplementation period, ranging from one to six months.
The evidence suggests that regular omega-3 supplementation could be crucial for individuals with atherosclerosis, potentially improving their health outcomes and lowering cardiac risks. Given the study’s findings, we advocate for reassessing dietary recommendations and considering higher daily intake allowances for omega-3s in these patients.
Our exploration revealed that dosages between 1.8 grams and 3.4 grams per day, over a span of three to six months, were effective in elevating omega-3 levels to therapeutic targets. Higher doses, at 4.4 grams or more, showed similar benefits even with a shorter supplementation period, ranging from one to six months.
The evidence suggests that regular omega-3 supplementation could be crucial for individuals with atherosclerosis, potentially improving their health outcomes and lowering cardiac risks. Given the study’s findings, we advocate for reassessing dietary recommendations and considering higher daily intake allowances for omega-3s in these patients.
Read More
9
Eicosapentaenoic acid combats atherosclerosis
The sphingosine-1-phosphate receptor 1 mediates the atheroprotective effect of eicosapentaenoic acid.
Focuses on isolated EPA effects
We explored how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, affects arteriosclerosis, specifically by examining its active metabolite, 17,18-epoxyeicosatetraenoic acid (17,18-EEQ). Our investigation revealed that 17,18-EEQ has the power to inhibit inflammation and endothelial activation, which are key factors in the development of atherosclerosis.
We found that this metabolite works through its interaction with a specific receptor, sphingosine-1-phosphate receptor 1 (S1PR1), in endothelial cells. In our study, when using male mice that lacked S1PR1, the protective effects of both 17,18-EEQ and purified EPA were noticeably absent. This emphasizes the importance of S1PR1 in mediating the benefits of EPA.
Mechanistically, we discovered that 17,18-EEQ promotes the activation of endothelial nitric oxide synthase (eNOS), which is vital for maintaining healthy blood vessels. This activation relies on a signaling pathway involving calcium release. We also noted that a prescription drug containing purified EPA, called Vascepa, exhibited cardiovascular benefits through this 17,18-EEQ-S1PR1 pathway.
Collectively, our findings highlight the potential of EPA and its metabolites as valuable tools in combating atherosclerosis, which could pave the way for new therapeutic strategies aimed at improving cardiovascular health.
We found that this metabolite works through its interaction with a specific receptor, sphingosine-1-phosphate receptor 1 (S1PR1), in endothelial cells. In our study, when using male mice that lacked S1PR1, the protective effects of both 17,18-EEQ and purified EPA were noticeably absent. This emphasizes the importance of S1PR1 in mediating the benefits of EPA.
Mechanistically, we discovered that 17,18-EEQ promotes the activation of endothelial nitric oxide synthase (eNOS), which is vital for maintaining healthy blood vessels. This activation relies on a signaling pathway involving calcium release. We also noted that a prescription drug containing purified EPA, called Vascepa, exhibited cardiovascular benefits through this 17,18-EEQ-S1PR1 pathway.
Collectively, our findings highlight the potential of EPA and its metabolites as valuable tools in combating atherosclerosis, which could pave the way for new therapeutic strategies aimed at improving cardiovascular health.
Read More
8
Eicosapentaenoic acid reduces inflammation
Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?
Highlights selective EPA effects
We investigated how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, could influence arterial inflammation in individuals with elevated lipoprotein(a) levels, a known risk factor for heart disease. In this pilot study, we focused on 12 patients who had stable coronary artery disease and were already on cholesterol-lowering treatments.
Over a 12-week period, participants received high doses of omega-3 fatty acids at 3.6 grams per day. We measured their arterial inflammation using advanced imaging techniques before and after the treatment period. The results were promising: we found that the omega-3 treatment significantly reduced plasma triglycerides, lipoprotein(a) levels, and arterial inflammation, as indicated by a decrease in a specific measurement known as the SUVmax.
Notably, the reduction in arterial inflammation seemed to correlate strongly with the patients’ levels of EPA, but not with docosahexaenoic acid (DHA) or triglycerides. This suggests that EPA may play a unique role in directly impacting arterial health in patients with elevated Lp(a).
In summary, our findings indicate that high doses of omega-3 fatty acids, particularly EPA, could be beneficial in reducing arterial inflammation in patients at risk of cardiovascular disease. This could pave the way for new treatments targeting arterial health in those with elevated lipoprotein(a).
Over a 12-week period, participants received high doses of omega-3 fatty acids at 3.6 grams per day. We measured their arterial inflammation using advanced imaging techniques before and after the treatment period. The results were promising: we found that the omega-3 treatment significantly reduced plasma triglycerides, lipoprotein(a) levels, and arterial inflammation, as indicated by a decrease in a specific measurement known as the SUVmax.
Notably, the reduction in arterial inflammation seemed to correlate strongly with the patients’ levels of EPA, but not with docosahexaenoic acid (DHA) or triglycerides. This suggests that EPA may play a unique role in directly impacting arterial health in patients with elevated Lp(a).
In summary, our findings indicate that high doses of omega-3 fatty acids, particularly EPA, could be beneficial in reducing arterial inflammation in patients at risk of cardiovascular disease. This could pave the way for new treatments targeting arterial health in those with elevated lipoprotein(a).
Read More
Most Useful Reviews
8.8
Stable health checkup
For managing arteriosclerosis, it’s best to control it through diet, although taking omega can be challenging. I have my husband, who has high triglyceride levels, take it daily. The capsules are somewhat large, but one can adapt to them. I have been taking it for many years, and as my health check-up results are stable, I will continue with it.
Read More
7
Risk reduction noted
It reduces the risk of arteriosclerosis and assists in maintaining healthy triglyceride levels.
Read More
Most Recommended Products for Arteriosclerosis
Doctor's Best High Absorption CoQ10 with BioPerine®
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Very Good
Based on 2 Reviews
8.8
Solgar Naturally Sourced Vitamin E
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Very Good
Based on 2 Reviews
8.6
NOW Foods Omega-3 Fish Oil
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
6.9
USERS' SCORE
Very Good
Based on 2 Reviews
8.8
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
6.9
9
Eicosapentaenoic acid combats atherosclerosis
The sphingosine-1-phosphate receptor 1 mediates the atheroprotective effect of eicosapentaenoic acid.
Focuses on isolated EPA effects
We explored how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, affects arteriosclerosis, specifically by examining its active metabolite, 17,18-epoxyeicosatetraenoic acid (17,18-EEQ). Our investigation revealed that 17,18-EEQ has the power to inhibit inflammation and endothelial activation, which are key factors in the development of atherosclerosis.
We found that this metabolite works through its interaction with a specific receptor, sphingosine-1-phosphate receptor 1 (S1PR1), in endothelial cells. In our study, when using male mice that lacked S1PR1, the protective effects of both 17,18-EEQ and purified EPA were noticeably absent. This emphasizes the importance of S1PR1 in mediating the benefits of EPA.
Mechanistically, we discovered that 17,18-EEQ promotes the activation of endothelial nitric oxide synthase (eNOS), which is vital for maintaining healthy blood vessels. This activation relies on a signaling pathway involving calcium release. We also noted that a prescription drug containing purified EPA, called Vascepa, exhibited cardiovascular benefits through this 17,18-EEQ-S1PR1 pathway.
Collectively, our findings highlight the potential of EPA and its metabolites as valuable tools in combating atherosclerosis, which could pave the way for new therapeutic strategies aimed at improving cardiovascular health.
We found that this metabolite works through its interaction with a specific receptor, sphingosine-1-phosphate receptor 1 (S1PR1), in endothelial cells. In our study, when using male mice that lacked S1PR1, the protective effects of both 17,18-EEQ and purified EPA were noticeably absent. This emphasizes the importance of S1PR1 in mediating the benefits of EPA.
Mechanistically, we discovered that 17,18-EEQ promotes the activation of endothelial nitric oxide synthase (eNOS), which is vital for maintaining healthy blood vessels. This activation relies on a signaling pathway involving calcium release. We also noted that a prescription drug containing purified EPA, called Vascepa, exhibited cardiovascular benefits through this 17,18-EEQ-S1PR1 pathway.
Collectively, our findings highlight the potential of EPA and its metabolites as valuable tools in combating atherosclerosis, which could pave the way for new therapeutic strategies aimed at improving cardiovascular health.
Read More
9
Icosapent ethyl improves heart function
Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT.
Relevant to arteriosclerosis research
We explored the effects of Icosapent ethyl (IPE) on coronary physiology, particularly in the context of arteriosclerosis. This investigation was part of a larger trial known as EVAPORATE, which had previously shown that IPE significantly reduced plaque buildup in patients already on statin therapy. Our study utilized advanced imaging techniques through coronary computed tomography angiography (CTA) to evaluate the changes in blood flow and artery function after treatment with IPE compared to a placebo.
With 47 patients and 507 coronary lesions assessed at various intervals over 18 months, we measured the fractional flow reserve (FFRCT) in the most diseased artery of each participant. Interestingly, while the initial FFRCT values were similar between those receiving IPE and placebo, significant improvements were noted at the 9- and 18-month follow-ups for the IPE group.
These findings indicate that Icosapent ethyl not only reduces plaque but also improves coronary blood flow over time. Such benefits lend credence to the findings from the REDUCE-IT trial, where IPE was associated with lower ischemic events, including heart attacks. Our investigation paves the way for understanding the underlying mechanisms of IPE’s positive effects on heart health.
With 47 patients and 507 coronary lesions assessed at various intervals over 18 months, we measured the fractional flow reserve (FFRCT) in the most diseased artery of each participant. Interestingly, while the initial FFRCT values were similar between those receiving IPE and placebo, significant improvements were noted at the 9- and 18-month follow-ups for the IPE group.
These findings indicate that Icosapent ethyl not only reduces plaque but also improves coronary blood flow over time. Such benefits lend credence to the findings from the REDUCE-IT trial, where IPE was associated with lower ischemic events, including heart attacks. Our investigation paves the way for understanding the underlying mechanisms of IPE’s positive effects on heart health.
Read More
8
Icosapent ethyl reduces cardiovascular events
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Study focused on cardiovascular outcomes
We aimed to explore the impact of icosapent ethyl on major cardiovascular events, particularly in patients with atherosclerotic cardiovascular disease (ASCVD). In a robust trial involving nearly 6,000 participants, we carefully monitored the effects of this treatment over a median duration of 4.8 years.
Icosapent ethyl, a form of omega-3 fatty acid, demonstrated a significant reduction in the risk of major adverse cardiovascular events (MACE), including non-fatal heart attacks and strokes. Our findings highlighted that the treatment was beneficial across different levels of baseline cardiovascular risk.
We observed that patients at the highest risk experienced the most considerable absolute benefits, making the treatment particularly valuable for them. Although the absolute risk reduction increased with higher baseline risk, it consistently showed efficacy for all participants suffering from elevated triglycerides.
In conclusion, our study suggests that icosapent ethyl is an effective option for reducing cardiovascular risks in patients dealing with atherosclerosis, regardless of their initial risk level.
Icosapent ethyl, a form of omega-3 fatty acid, demonstrated a significant reduction in the risk of major adverse cardiovascular events (MACE), including non-fatal heart attacks and strokes. Our findings highlighted that the treatment was beneficial across different levels of baseline cardiovascular risk.
We observed that patients at the highest risk experienced the most considerable absolute benefits, making the treatment particularly valuable for them. Although the absolute risk reduction increased with higher baseline risk, it consistently showed efficacy for all participants suffering from elevated triglycerides.
In conclusion, our study suggests that icosapent ethyl is an effective option for reducing cardiovascular risks in patients dealing with atherosclerosis, regardless of their initial risk level.
Read More
8
Eicosapentaenoic acid aids plaque regression
Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease.
Involves both acids; limited isolation
We analyzed how eicosapentaenoic acid, along with docosahexaenoic acid, influences the progression of coronary fatty plaque in patients with stable coronary artery disease. Over a period of 30 months, 240 participants were divided into two groups; one received a daily supplement of eicosapentaenoic acid and docosahexaenoic acid, while the other received no treatment. This setup allowed us to compare the effects on plaque regression and cardiac events between both groups.
Our findings revealed that participants who experienced a reduction in triglyceride levels—averaging a 14.9% decrease—also showed a notable regression of fatty plaque. Moreover, patients who saw plaque regression enjoyed significantly fewer cardiac events compared to those whose plaque progressed, with 5% reporting events against 22.3% in the other group.
We identified key predictors for plaque regression, which included having a systolic blood pressure below 125 mm Hg and a non-high-density lipoprotein cholesterol level below 2.59 mmol/L. Interestingly, normotensive patients (those with normal blood pressure) benefitted more from the treatment, seeing both a reduction in plaque and inflammation compared to those with hypertension, who showed no significant changes.
Overall, our study sheds light on how eicosapentaenoic acid may contribute to improved heart health, particularly among individuals with specific blood pressure and cholesterol levels. It opens the door for further research on how managing inflammation could enhance plaque regression in patients with coronary artery disease.
Our findings revealed that participants who experienced a reduction in triglyceride levels—averaging a 14.9% decrease—also showed a notable regression of fatty plaque. Moreover, patients who saw plaque regression enjoyed significantly fewer cardiac events compared to those whose plaque progressed, with 5% reporting events against 22.3% in the other group.
We identified key predictors for plaque regression, which included having a systolic blood pressure below 125 mm Hg and a non-high-density lipoprotein cholesterol level below 2.59 mmol/L. Interestingly, normotensive patients (those with normal blood pressure) benefitted more from the treatment, seeing both a reduction in plaque and inflammation compared to those with hypertension, who showed no significant changes.
Overall, our study sheds light on how eicosapentaenoic acid may contribute to improved heart health, particularly among individuals with specific blood pressure and cholesterol levels. It opens the door for further research on how managing inflammation could enhance plaque regression in patients with coronary artery disease.
Read More
8
Eicosapentaenoic acid reduces inflammation
Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?
Highlights selective EPA effects
We investigated how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, could influence arterial inflammation in individuals with elevated lipoprotein(a) levels, a known risk factor for heart disease. In this pilot study, we focused on 12 patients who had stable coronary artery disease and were already on cholesterol-lowering treatments.
Over a 12-week period, participants received high doses of omega-3 fatty acids at 3.6 grams per day. We measured their arterial inflammation using advanced imaging techniques before and after the treatment period. The results were promising: we found that the omega-3 treatment significantly reduced plasma triglycerides, lipoprotein(a) levels, and arterial inflammation, as indicated by a decrease in a specific measurement known as the SUVmax.
Notably, the reduction in arterial inflammation seemed to correlate strongly with the patients’ levels of EPA, but not with docosahexaenoic acid (DHA) or triglycerides. This suggests that EPA may play a unique role in directly impacting arterial health in patients with elevated Lp(a).
In summary, our findings indicate that high doses of omega-3 fatty acids, particularly EPA, could be beneficial in reducing arterial inflammation in patients at risk of cardiovascular disease. This could pave the way for new treatments targeting arterial health in those with elevated lipoprotein(a).
Over a 12-week period, participants received high doses of omega-3 fatty acids at 3.6 grams per day. We measured their arterial inflammation using advanced imaging techniques before and after the treatment period. The results were promising: we found that the omega-3 treatment significantly reduced plasma triglycerides, lipoprotein(a) levels, and arterial inflammation, as indicated by a decrease in a specific measurement known as the SUVmax.
Notably, the reduction in arterial inflammation seemed to correlate strongly with the patients’ levels of EPA, but not with docosahexaenoic acid (DHA) or triglycerides. This suggests that EPA may play a unique role in directly impacting arterial health in patients with elevated Lp(a).
In summary, our findings indicate that high doses of omega-3 fatty acids, particularly EPA, could be beneficial in reducing arterial inflammation in patients at risk of cardiovascular disease. This could pave the way for new treatments targeting arterial health in those with elevated lipoprotein(a).
Read More
User Reviews
USERS' SCORE
Very Good
Based on 2 Reviews
7.9
8.8
Stable health checkup
For managing arteriosclerosis, it’s best to control it through diet, although taking omega can be challenging. I have my husband, who has high triglyceride levels, take it daily. The capsules are somewhat large, but one can adapt to them. I have been taking it for many years, and as my health check-up results are stable, I will continue with it.
Read More
7
Risk reduction noted
It reduces the risk of arteriosclerosis and assists in maintaining healthy triglyceride levels.
